False negative bone scintigraphy in a patient with primary breast cancer: A possible transient phenomenon of bisphosphonate (alendronate) treatment

Tumori

Volumn 91, Issue 1, 2005, Pages 77-80

  Demirkan, Binnaz ^a   Başkan, Zuhal ^a   Alacacioǧlu, Ahmet ^a   Görken, Iknur Bilkay ^a   Bekiş, Recep ^a   Ada, Emel ^a   Osma, Emine ^a   Alakavuklar, Mehmet ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

99mTc MDP bone scan; Bisphosphonate; Bone metastasis; Breast cancer

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; MEDRONATE TECHNETIUM TC 99M;

AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFECT; FEMALE; HUMAN; LABORATORY DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PHENOMENOLOGY;

EID: 16344394743     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100115     Document Type: Article

References (12)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin, 54: 8-29, 2004.
2. Van Poznak C: How are bisphosphonates used today in breast cancer clinical practice? Semin Oncol, 28: 69-74, 2001.
3. Altehoefer C, Ghanem N, Högerle S, Moser E, Langer M: Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. Eur J Radiol, 40: 16-23, 2001.
4. Myers RE, Johnston M, Pritchard K, Levine M, Oliver T, the Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative: Baseline staging tests in primary breast cancer: a practice guideline. CMAJ, 164: 1439-1444, 2001.
5. Yip CH, Paramsothy M: Value of routine 99mTc-MDP bone scintigraphy in the detection of occult skeletal metastases in women with primary breast cancer. Breast, 8: 267-269, 1999.
6. Moore AEB, Hain SF, Blake GM, Fogelman I: Validation of ultrafiltration as a method of measuring free 99mTc-MDP. J Nucl Med, 44: 891-897, 2003.
7. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol, 21: 4042-4057, 2003.
8. Huffman A, Stepensky D, Ezra A, Van Gelder JM, Colomb G: Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm, 220: 1-11, 2001.
9. Demirci H, Shields CL, Chao A, Shields JA: Uveal metastasis from breast cancer in 264 patients. Am J Ophthalmol, 136: 264-271, 2003.
10. Blake GM, Park-Holohan SJ, Fogelman I: Quantitative studies of bone in postmenopausal women using 18F-fluoride and 99mTc-methylene diphosphonate. J Nucl Med, 43: 338-345, 2002.
11. Brenner W, Bohuslavizki KH, Sieweke N, Tinnemeyer S, Clausen M, Henze E: Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med, 24: 1284-1290, 1997.
12. Porras AG, Holland SD, Gertz BJ: Pharmacokinetics of alendronate. Clin Pharmacokinet, 36: 315-328, 1999.